Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Share-based Compensation (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Share-based Compensation for 8 consecutive years, with $760000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation fell 58.24% year-over-year to $760000.0, compared with a TTM value of $4.2 million through Sep 2025, down 50.22%, and an annual FY2024 reading of $8.2 million, down 5.56% over the prior year.
  • Share-based Compensation was $760000.0 for Q3 2025 at X4 Pharmaceuticals, up from $748000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $2.5 million in Q4 2023 and bottomed at $519000.0 in Q1 2025.
  • Average Share-based Compensation over 5 years is $1.6 million, with a median of $1.6 million recorded in 2021.
  • The sharpest move saw Share-based Compensation surged 129.36% in 2023, then plummeted 70.16% in 2025.
  • Year by year, Share-based Compensation stood at $1.6 million in 2021, then plummeted by 31.2% to $1.1 million in 2022, then soared by 129.36% to $2.5 million in 2023, then fell by 12.68% to $2.2 million in 2024, then tumbled by 65.72% to $760000.0 in 2025.
  • Business Quant data shows Share-based Compensation for XFOR at $760000.0 in Q3 2025, $748000.0 in Q2 2025, and $519000.0 in Q1 2025.